Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 14
HOS-114824 · Präparat HOS-094169
No clinically significant change is observed in tipranavir PK parameters. Rifampicin Co-administration of protease Concomitant use of Aptivus, co- inhibitors with rifampicin administered with low dose substantially decreases protease ritonavir, and rifampicin is inhibitor concentrations. In the contraindicated (see section 4.3). case of tipranavir co- Alternate antimycobacterial administered with low dose agents such as rifabutin should be ritonavir, concomitant use with considered. rifampicin is expected to result in sub-optimal levels of tipranavir which may lead to loss of virologic response and possible resistance to tipranavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) rifabutin (HOS-086262) lead (HOS-085592) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 22c480831bf584b925ad93bcda9cdab953947ff091675429065beb340adfa99a · Zeichen 25327–26353 im Abschnitt